| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Cardiovascular Research Institute, Comprehensive Cancer Center, and the Department of Anatomy, University of California, San Francisco, California
Often described as incomplete or absent, the basement membrane of blood vessels in tumors has attracted renewed attention as a source of angiogenic and anti-angiogenic molecules, site of growth factor binding, participant in angiogenesis, and potential target in cancer therapy. This study evaluated the composition, extent, and structural integrity of the basement membrane on blood vessels in three mouse tumor models: spontaneous RIP-Tag2 pancreatic islet tumors, MCa-IV mammary carcinomas, and Lewis lung carcinomas. Tumor vessels were identified by immunohistochemical staining for the endothelial cell markers CD31, endoglin (CD105), vascular endothelial growth factor receptor-2, and integrin alpha5 (CD49e). Confocal microscopic studies revealed that basement membrane identified by type IV collagen immunoreactivity covered >99.9% of the surface of blood vessels in the three tumors, just as in normal pancreatic islets. Laminin, entactin/nidogen, and fibronectin immunoreactivities were similarly ubiquitous on tumor vessels. Holes in the basement membrane, found by analyzing 1-µm confocal optical sections, were <2.5 µm in diameter and involved only 0.03% of the vessel surface. Despite the extensive vessel coverage, the basement membrane had conspicuous structural abnormalities, including a loose association with endothelial cells and pericytes, broad extensions away from the vessel wall, and multiple layers visible by electron microscopy. Type IV collagen-immunoreactive sleeves were also present on endothelial sprouts, supporting the idea that basement membrane is present where sprouts grow and regress. These findings indicate that basement membrane covers most tumor vessels but has profound structural abnormalities, consistent with the dynamic nature of endothelial cells and pericytes in tumors.
This article has been cited by other articles:
 |
|
 |
|
  P. BALUK and D. M. MCDONALD Markers for Microscopic Imaging of Lymphangiogenesis and Angiogenesis Ann. N.Y. Acad. Sci., May 1, 2008; 1131(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Pla, C. Grange, S. Antoniotti, C. Tomatis, A. Merlino, B. Bussolati, and L. Munaron Arachidonic Acid-Induced Ca2+ Entry Is Involved in Early Steps of Tumor Angiogenesis Mol. Cancer Res., April 1, 2008; 6(4): 535 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H.E. Baker, K. E. Lindquist, L. A. Huxham, A. H. Kyle, J. T. Sy, and A. I. Minchinton Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts Clin. Cancer Res., April 1, 2008; 14(7): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhou, P. Guo, and J. M. Gallo Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide Clin. Cancer Res., March 1, 2008; 14(5): 1540 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kadenhe-Chiweshe, J. Papa, K. W. McCrudden, J. Frischer, J.-O Bae, J. Huang, J. Fisher, J. H. Lefkowitch, N. Feirt, J. Rudge, et al. Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation Mol. Cancer Res., January 1, 2008; 6(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. DeWever, F. Frerart, C. Bouzin, C. Baudelet, R. Ansiaux, P. Sonveaux, B. Gallez, C. Dessy, and O. Feron Caveolin-1 Is Critical for the Maturation of Tumor Blood Vessels through the Regulation of Both Endothelial Tube Formation and Mural Cell Recruitment Am. J. Pathol., November 1, 2007; 171(5): 1619 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Larrivee, C. Freitas, M. Trombe, X. Lv, B. DeLafarge, L. Yuan, K. Bouvree, C. Breant, R. Del Toro, N. Brechot, et al. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis Genes & Dev., October 1, 2007; 21(19): 2433 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sennino, B. L. Falcon, D. McCauley, T. Le, T. McCauley, J. C. Kurz, A. Haskell, D. M. Epstein, and D. M. McDonald Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102 Cancer Res., August 1, 2007; 67(15): 7358 - 7367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ayers, J. Fargnoli, A. Lewin, Q. Wu, and J. S. Platero Discovery and Validation of Biomarkers that Respond to Treatment with Brivanib Alaninate, a Small-Molecule VEGFR-2/FGFR-1 Antagonist Cancer Res., July 15, 2007; 67(14): 6899 - 6906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Gerber, V. Y. Rybalko, C. E. Bigelow, A. A. Lugade, T. H. Foster, J. G. Frelinger, and E. M. Lord Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth Am. J. Pathol., November 1, 2006; 169(5): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Cassoni, T. Marrocco, B. Bussolati, E. Allia, L. Munaron, A. Sapino, and G. Bussolati Oxytocin Induces Proliferation and Migration in Immortalized Human Dermal Microvascular Endothelial Cells and Human Breast Tumor-Derived Endothelial Cells Mol. Cancer Res., June 1, 2006; 4(6): 351 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res., March 15, 2006; 66(6): 3303 - 3309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Campochiaro and the First ARVO/Pfizer Institute Working Group Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 462 - 474. [Full Text] [PDF]
|
|
|
|
|
|
T. Nakahara, S. M. Norberg, D. R. Shalinsky, D. D. Hu-Lowe, and D. M. McDonald Effect of Inhibition of Vascular Endothelial Growth Factor Signaling on Distribution of Extravasated Antibodies in Tumors Cancer Res., February 1, 2006; 66(3): 1434 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kamba, B. Y. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H560 - H576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Akiyama, K. A. Mohamedali, R. L. e Silva, S. Kachi, J. Shen, C. Hatara, N. Umeda, S. F. Hackett, S. Aslam, M. Krause, et al. Vascular Targeting of Ocular Neovascularization with a Vascular Endothelial Growth Factor121/Gelonin Chimeric Protein Mol. Pharmacol., December 1, 2005; 68(6): 1543 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. McDonald and P. Baluk Imaging of Angiogenesis in Inflamed Airways and Tumors: Newly Formed Blood Vessels Are Not Alike and May Be Wildly Abnormal: Parker B. Francis Lecture Chest, December 1, 2005; 128(6_suppl): 602S - 608S. [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Davis and D. R. Senger Endothelial Extracellular Matrix: Biosynthesis, Remodeling, and Functions During Vascular Morphogenesis and Neovessel Stabilization Circ. Res., November 25, 2005; 97(11): 1093 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. di Tomaso, D. Capen, A. Haskell, J. Hart, J. J. Logie, R. K. Jain, D. M. McDonald, R. Jones, and L. L. Munn Mosaic Tumor Vessels: Cellular Basis and Ultrastructure of Focal Regions Lacking Endothelial Cell Markers Cancer Res., July 1, 2005; 65(13): 5740 - 5749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Parsons-Wingerter, I. M. Kasman, S. Norberg, A. Magnussen, S. Zanivan, A. Rissone, P. Baluk, C. J. Favre, U. Jeffry, R. Murray, et al. Uniform Overexpression and Rapid Accessibility of {alpha}5{beta}1 Integrin on Blood Vessels in Tumors Am. J. Pathol., July 1, 2005; 167(1): 193 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Magnussen, I. M. Kasman, S. Norberg, P. Baluk, R. Murray, and D. M. McDonald Rapid Access of Antibodies to {alpha}5{beta}1 Integrin Overexpressed on the Luminal Surface of Tumor Blood Vessels Cancer Res., April 1, 2005; 65(7): 2712 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Pauli, H. Tang, J. Wang, P. Bohlen, R. Posser, T. Hartman, M. V. Sauer, J. Kitajewski, and R. C. Zimmermann The Vascular Endothelial Growth Factor (VEGF)/VEGF Receptor 2 Pathway Is Critical for Blood Vessel Survival in Corpora Lutea of Pregnancy in the Rodent Endocrinology, March 1, 2005; 146(3): 1301 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lefranc, T. Mijatovic, V. Mathieu, S. Rorive, C. Decaestecker, O. Debeir, J. Brotchi, P. Van Ham, I. Salmon, and R. Kiss Characterization of Gastrin-Induced Proangiogenic Effects In vivo in Orthotopic U373 Experimental Human Glioblastomas and In vitro in Human Umbilical Vein Endothelial Cells Clin. Cancer Res., December 15, 2004; 10(24): 8250 - 8265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hida, Y. Hida, D. N. Amin, A. F. Flint, D. Panigrahy, C. C. Morton, and M. Klagsbrun Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities Cancer Res., November 15, 2004; 64(22): 8249 - 8255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Baluk, C. G. Lee, H. Link, E. Ator, A. Haskell, J. A. Elias, and D. M. McDonald Regulated Angiogenesis and Vascular Regression in Mice Overexpressing Vascular Endothelial Growth Factor in Airways Am. J. Pathol., October 1, 2004; 165(4): 1071 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston, G. D. Yancopoulos, et al. Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts Am. J. Pathol., July 1, 2004; 165(1): 35 - 52. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
